- Algernon Pharmaceuticals (AGN) has signed a clinical trial agreement with Yale University to investigate multiple intravenous doses of DMT to treat depression
- Algernon will provide cGMP N, N-Dimethyltryptamine (DMT, a hallucinogenic tryptamine drug) for the study. In return, the company will jointly own intellectual property around the clinical use of DMT arising from the study developed jointly with Yale
- The study will compare different bolus and constant infusion dosing regimens of DMT in healthy control participants and individuals with depression
- Algernon Pharmaceuticals (AGN) is down 6.90 per cent, trading at $2.70 per share as of 11 am ET
Algernon Pharmaceuticals (AGN) has signed a clinical trial agreement with Yale University to investigate multiple intravenous doses of DMT to treat depression.
Algernon will provide cGMP N, N-Dimethyltryptamine (DMT, a hallucinogenic tryptamine drug) for the study. In return, the company will jointly own intellectual property around the clinical use of DMT arising from the study developed jointly with Yale.
The study will compare different bolus and constant infusion dosing regimens of DMT in healthy control participants and individuals with depression.
The company has the option to negotiate licenses to IP developed jointly and solely by Yale and will also receive data from the study, which may assist in its DMT stroke research program.
The trial’s principal investigator is Professor Deepak D’Souza, MBBS MD, Professor of Psychiatry and Director of the Schizophrenia Neuropharmacology Research Group at the Yale University School of Medicine, an experienced researcher with DMT and other controlled substances.
Algernon’s CEO, Christopher J. Moreau, added that after careful consideration, the company chose to support Dr. D’Souza’s clinical DMT study and work with Yale University.
“Although the treatment of psychiatric disorders with DMT is not the company’s current focus, we have patents pending on novel forms of DMT which could potentially be used across a broad range of diseases. In addition, we believe the data generated from this study may help inform Algernon’s stroke research program.”
Algernon Pharmaceuticals Inc. is a Canadian clinical-stage drug development company investigating multiple drugs with global unmet medical needs.
Algernon Pharmaceuticals (AGN) is down 6.90 per cent, trading at $2.70 per share as of 11 am ET.
